


# Ready, Set, #CROI2023


## Prepare for the 30th Year of CROI



Webinar brought to you by the CROI Community Liaisons, The Choice Agenda, and Friends



- Argentina
- Belgium
- Botswana
- Brazil
- Burundi
- Canada
- Côte d'Ivoire
- Denmark
- Eswatini
- France
- Gambia
- Italy
- Kenya



**26 countries**

**172 webinar registrants**


- Latvia
- Malawi
- Nigeria
- Peru
- South Africa
- Switzerland
- Tanzania
- Thailand
- Uganda
- United Kingdom
- United States
- Zambia
- Zimbabwe

**Webinar brought to you by the CROI Community Liaisons, The Choice Agenda, and Friends**

The background is a vibrant green gradient, transitioning from a darker green at the top to a lighter, almost white green at the bottom. Overlaid on this gradient is a complex network of white dots of varying sizes, connected by thin, light-colored lines. The dots and lines are more densely packed and brighter in the upper half of the image, creating a sense of depth and connectivity. The overall effect is that of a digital or biological network.

Thank you for joining us.

# Webinar Logistics



- This call will be recorded. Your presence = consent.
- We are providing closed captions.
- Please stay on mute, unless you are speaking.
- Please comment, ask questions, share info/resources in the chat.
- Let's hear your voice and see your face too. Raise hand to speak on camera.
- **We will share links to recording and slides in follow-up email.**
- Access TCA webinar resources here:
  - [www.avac.org/choice-agenda](http://www.avac.org/choice-agenda)

# Decolonizing Global Public Health

What Will it Take to **Dismantle  
Racism** and White Supremacy?

February 16, 2023

Register now → [tinyurl.com/decolonizepublichealth](https://tinyurl.com/decolonizepublichealth)




Ready, Set, #CROI2023



Don't forget to press record!

**Connect Virtually!**




# CROI 2023 Community

---

Join the chat → <https://tinyurl.com/croi2023communitychat>

Connect in Person!



## Community Networking Zone

Find our tables in the Poster Hall  
During Poster Sessions and otherwise





# MARGARITA BREAKFAST CLUBS

AT #CROI2022

**FEBRUARY 14-24 2022**

7:15 – 8:15 AM MOUNTAIN / DENVER TIME  
(15:15 – 16:45 CET)

REGISTER AT ZOOM

**MONDAY FEBRUARY 14: FROM LONG TO LONGER - HOW NEW ARVS ARE REWRITING THE SCRIPT FOR HIV PREVENTION AND TREATMENT DR. CHLOE ORKIN**

**WEDNESDAY FEBRUARY 16: RIVER DEEP, MOUNTAIN HIGH: PATHWAYS TOWARDS A CURE FOR HIV DR. KATHARINE BAR AND MOSES SUPERCHARGER**


**TUESDAY FEBRUARY 22: AGING WITH HIV – FRAILTY, COMORBIDITIES AND A CALL TO ACTION DR. KRISTINE ERLANDSON AND JULES LEVIN**

**WEDNESDAY FEBRUARY 23: RINGS AND INJECTABLE THINGS: MOVING FROM OPTIONS TO CHOICES FOR HIV PREVENTION IN CISGENDER WOMEN DRs. SINEAD DELANY-MORETLWE AND KENNETH NGURE**

**THURSDAY FEBRUARY 24: LONG COVID – WHAT WE KNOW, WHAT WE NEED TO KNOW, AND WHAT WE NEED TO DO DR. STEVE DEEKS AND JD DAVIDS**

Open to everyone!  
CROI registration is not required

Organised by  
CROI's Community Liaison Subcommittee in collaboration with AVAC, EATG and a range of global partners.  
Many thanks to Danielle Campbell, Michael Louella and Jeff Taylor





# Virtual

DAILY COMMUNITY  
RESEARCH UPDATES  
FROM CROI 2022

## MARGARITA BREAKFAST CLUBS **2023**

# Back by popular demand

2023 schedule  
coming soon – **stay  
tuned**

Programming on  
**Monday (20<sup>th</sup>),  
Tuesday (21<sup>st</sup>) and  
Wednesday (22<sup>nd</sup>)**  
mornings

**7:00 am – 8:00 am**  
each morning

Zoom – **all are  
welcome**  
regardless of CROI  
registration

## Today's Playlist


- Don't You Know [Kungs]
- Mystify [INXS]
- Why? [Bronski Beat]
- Science [Burna Boy]
- Smells Like Teen Spirit [Nirvana]
- Crazy [Seal]
- Rain on Me [Lady Gaga & Ariana Grande]
- Seattle [Perry Como]
- All Cried Out [Alison Moyet]
- Shiny Happy People [REM]

Ready, Set, #CROI2023



# Agenda

- Welcome
- Meet CROI Chair, Vice-Chairs
  - Dr. James Hoxie, Dr. Diane Havlir and Dr. Landon Myer
- Meet CROI Community Liaisons
  - Dawn Averitt, Ntando Yola, Jim Pickett
  - Shout out Michael Louella, UW
- Meet IAS-USA's Executive Director
  - Donna Jacobsen
- Meet CROI Scientific Program Committee member
  - Dr. Carlos del Rio
- Strategies for navigating CROI
  - Deirdre Grant, AVAC
- Improving our Research Literacy
  - Jessica Salzwedel, AVAC and Victoria Sperling-Walker, BIDMC




Ready, Set, #CROI2023

— 30<sup>th</sup> —

# CROI2023

Conference on Retroviruses and Opportunistic Infections




# Welcome Back to Seattle!



CROI

# CROI 2023: Newly Constructed Summit Building, Seattle Convention Center



# Who will be at CROI 2023

- 3500 attendees overall
  - 3000 in person (well above the 1500 to 2000 we expected)
  - 500 attending virtually
- Approximately 60% from the US and 40% outside the US



# CROI 2023: Scientific Program

- [www.croiconference.org/preliminary-agenda/](http://www.croiconference.org/preliminary-agenda/) :REFRESH OFTEN!
- Opening Session: streamed live to the public
- Plenary sessions, symposia, themed discussions, and special sessions
- Original research: 1005 original research abstracts accepted
  - 115 oral abstracts
  - 834 poster abstracts
  - Of these, 228 cutting-edge SARS-CoV-2 and 61 mpox abstracts

# COVID-19 Precautions

**Please always wear your mask correctly during all conference sessions and in all conference rooms**

**Vaccination verification is required for all in-person attendees**


**If you experience COVID symptoms, test. If you test positive, please do not attend.**



# Conference Platform

The Conference Platform has many features to enhance your conference experience, including to:

- Watch live sessions
- View abstracts
- Create a personal calendar of the sessions you plan to attend
- Receive the latest changes/corrections to the CROI program
- View electronic posters
- Submit questions to live streamed presentations



— 30<sup>th</sup> —

# CROI 2023

Conference on Retroviruses  
and Opportunistic Infections



## Welcome to CROI 2023

### This Conference Platform is for Registered Attendees of CROI.

As a virtual attendee, you will have the ability to create your own digital schedule, watch live streamed sessions, view abstracts and posters, ask the presenter questions and chat with fellow attendees.


On-demand content will be available here. You will be able to take notes and save your place for future viewing.

### Login

If you have registered with us, please log in

**SIGN IN**

If you are having issues logging on please reach out to [support@e-attend.com](mailto:support@e-attend.com)



# CROI 2023

Conference on Retroviruses and Opportunistic Infections

[HOME](#) [SCHEDULE](#) [POSTERS](#)



[LIVE Sessions](#)

[On-Demand Sessions](#)

[Search](#)

[Connect with Colleagues](#)

[Poster Sessions](#)

    
[Abstract eBook](#)

[Program eGuide](#)

[Click Here for important information and announcements](#)

— 30<sup>th</sup> —  
**CROI** 2023



[Engage in the conversation on social #CROI2023](#)

# COMMUNITY EDUCATOR SCHOLARSHIP AWARDEES ACTIVITIES

## Margarita Breakfast Club

The Community Liaison Subcommittee and partners host **morning Zoom meetings with community members to review new data and presentations** at CROI. These meetings are **open to all community attendees**, including those attending virtually from various time zones around the world.

## Networking Area

**Poster Hall area** is the designated central meeting point for Community Educator Scholarship Awardees and other HIV community representatives and advocates

# CROI is...

- A great opportunity to learn and connect
- A great source of inspiration and motivation
- Full of cutting-edge science in plenaries, oral abstract sessions, symposia, poster sessions and more
- A rich resource you can tap throughout the year


# Getting the most out of CROI

- Have realistic expectations and take care of yourself
- Be prepared
  - *Create your own “track”*
  - *Review the program in advance and make your schedule*
    - Plenaries
    - Symposia
    - Oral abstract sessions
    - Themed discussions
    - Special sessions
    - Posters
- For those participating virtually, log in before the conference and acquaint yourself with the conference platform



# Create Your Own “Track”

- What do you want from CROI?
- What interests you most?
- What matters most to the community you serve?
- What is your area of focus?





# Review the Program Guide!


[www.croiconference.org/croi-2023-resources/](http://www.croiconference.org/croi-2023-resources/)


SUNDAY, FEBRUARY 19, 2023


**OPENING-01 OPENING SESSION** CME  
Flex C (Level 2) 5:00 PM - 7:20 PM


**WELCOME FROM THE CROI 2023 CHAIR**  
James Hoxie, University of Pennsylvania, Philadelphia, PA, USA 


**12 MODELING THE DYNAMICS OF HIV INFECTION: ESTABLISHING PARADIGMS FOR TREATMENT AND CURE**  
 Alan S. Perelson, Los Alamos National Laboratory, Los Alamos, NM, USA


**INTRODUCTION OF THE N'GALY-MANN LECTURE**  
 Diane V. Havlir, University of California San Francisco, San Francisco, CA, USA

**13 HIV AND GLOBAL HEALTH IN A PANDEMIC ERA**  
 Kevin M. De Cock, Centers for Disease Control and Prevention (former), Nairobi, Nairobi Area, Kenya

**INTRODUCTION OF THE MARTIN DELANEY PRESENTATION**  
 Dawn Averitt, The Well Project, Women's Research Initiative on HIV/AIDS, South Stratford, VT, USA

**14 COMMUNITY AND ADVOCATES ARE EQUAL PARTNERS IN RESEARCH AND DEVELOPMENT**  
 Yvette A. Raphael, Advocacy for Prevention of HIV and AIDS, Midrand, Gauteng, South Africa

**CROI AT 30: PROGRESS IN HIV THROUGH THE LENS OF FAUCI**  
INTRODUCTION OF DR ANTHONY FAUCI  
Robert Schooley, University of California San Diego, San Diego, CA, USA 


**CROI: A 30-YEAR CHRONICAL OF HIV/AIDS RESEARCH PROGRESS**  
Anthony S. Fauci, Former Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Washington, DC 


Opening Session, Plenaries, and Symposia by Day



MONDAY, FEBRUARY 20, 2023


**PLENARY-01 MONDAY PLENARY SESSION** CME  
Flex C (Level 2) 8:30 AM - 9:30 AM


**CROI PROGRAM COMMITTEE CHAIR WELCOME TO MONDAY**


**15 20 YEARS OF PEPFAR: LOOKING BACK, STRIDING FORWARD**  
 John Nkengasong, US Department of State, Washington, DC, USA

**16 THE PATH TO HEPATITIS B CURE**  
 Anna S. Lok, University of Michigan, Ann Arbor, MI, USA

**Moderators**  
Raphael J. Landovitz, University of California Los Angeles, Los Angeles, CA, USA   
Christina Psaros, Massachusetts General Hospital, Boston, MA, USA 

**23 FROM EFFICACY TO EFFECTIVENESS: CATALYZING ROLLOUT OF LONG ACTING PrEP**  
 Nyaradzo M. Mgodli, University of Zimbabwe, Harare, Harare, Zimbabwe

**24 AVOIDING DISPARITIES: NOT MAKING THE SAME MISTAKE AGAIN**  
 LaRon Nelson, Yale University, New Haven, CT, USA

**25 LA PrEP: WHAT WE KNOW AND WHAT WE STILL NEED TO KNOW**  
 Sunil S. Solomon, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Opening Session, Plenaries, and Symposia by Day - Monday

**SYMPOSIUM-09 SCIENCE COMMUNICATION IN THE AGE OF MISINFORMATION** CME  
Ballroom 2 (Level 5) 4:00 PM - 5:30 PM

**Objectives:** At the completion of the session, participants will be able to:



- Describe the history and current state of traditional media, social media and internet-based health information, misinformation, and disinformation
- Evaluate approaches to proactively address health literacy, vaccine uptake, and health communications
- Design effective communications to proactively address vaccine hesitancy

CROI 2023 31

Opening Session, Plenaries, and Symposia by Day

**Target Audience:** This session is directed to physicians and researchers interested in the communication of information to audiences with and without a training in science.

**Level of Knowledge:** It is assumed that participants are familiar with the contemporary issues in SARS-CoV-2, mpox, HIV, and related conditions.

**Moderators**  
Jonathan Mermin, Centers for Disease Control and Prevention, Atlanta, GA, USA   
Jon Cohen, Science, Cardiff By The Sea, CA, USA 



**SPECIAL SESSION-1 RESULTS FROM THE MOSAICO HIV VACCINE TRIAL AND FUTURE DIRECTIONS FOR HIV VACCINES**  
Flex A (Level 2) 5:40 PM - 6:00 PM

**Moderators**  
Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA 

**OVERVIEW OF THE MOSAICO HIV VACCINE TRIAL**  
 Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA

**HIV VACCINE DEVELOPMENT POST-MOSAICO**  
 Lawrence Corey, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

**Oral Abstract Session-08 ALL MODES LEAD TO PrEP**  
Ballroom 3 (Level 5) 10:00 AM - 12:00 PM

**Moderators**  
Jean-Michel Molina, University of Paris Cité, Hospital Saint Louis/Lariboisière, Paris, Ile-de-France, France   
Valdilea Veloso, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil 

**159 CABOTEGRAVIR PHARMACOLOGY IN THE BACKGROUND OF DELAYED INJECTIONS IN HPTN 084**  
10:05  
Mark A. Marzinke, Xu Guo, James Hughes, Brett Hanscom, Estelle Piwowar-Manning, Craig Hendrix, Scott Rose, Jim Rooney, Alex R. Rinehart, Susan Ford, Adeola Adeyeye, Myron S. Cohen, Mina Hosseinipour, Sinead Delany-Moretlwe  
**Research Group:** HPTN 084 Study Team

**160 THE LEVI SYNDROME: CHARACTERISTICS OF EARLY HIV INFECTION WITH CABOTEGRAVIR FOR PrEP**  
10:13  
Susan H. Eshleman, Jessica M. Fogel, Estelle Piwowar-Manning, Brett Hanscom, Alex R. Rinehart, Myron S. Cohen, Marybeth McCauley, Jennifer Farris, Adeola Adeyeye, Mina Hosseinipour, Beatriz Grinsztejn, Mark A. Marzinke, Sinead Delany-Moretlwe, Raphael J. Landovitz  
**Research Group:** for the HPTN 083 and 084 Study Teams

**161 CABOTEGRAVIR FOR HIV PrEP IN US BLACK MEN AND TRANSGENDER WOMEN WHO HAVE SEX WITH MEN**  
10:21  
Hyman Scott, Brett Hanscom, Craig Hutchinson, Jonathan Lucas, Aditya Gaur, Colleen Kelley, Debora Dubar, Paul Richardson, Jim Rooney, Alex R. Rinehart, Adeola Adeyeye, Beatriz Grinsztejn, Raphael J. Landovitz, Sheldon Fields  
**Research Group:** HPTN 083 Study Team

**162 CAB LA FOR HIV PREVENTION IN AFRICAN CISGENDER FEMALE ADOLESCENTS (HPTN 084-01)**  
10:29  
Sybil Hosek, Erica L. Hamilton, Julie Ngo, Yuqing Jiao, Brett Hanscom, Sinead Delany-Moretlwe, Nyaradzo M. Mgodli, Bekezela Siziba, Ishana Naidoo, BRENDA G. MIREMBE, Betty Kamira, Mark A. Marzinke, Cynthia McCoig, Hans Spiegel, Lynda Stranix-Chibanda  
**Research Group:** HPTN 08-01 Study Team

**163 8+ YEARS POOLED ANALYSIS: ADHERENCE AND HIV INCIDENCE IN 6000 WOMEN ON F/TDF FOR PrEP**  
11:00  
Jeanne Marrazzo, Marissa Becker, Linda-Gail Bekker, Connie Celum, Michael Kiragu, Ashley Leech, Allan Taylor, Faith Ussery, Juan Yang, Melanie de Boer, Christoph Carter, Moupali Das, Jared M. Baeten, Li Tao

**164 SAFETY AND PK/PD OF A TENOFOVIR ALAFENAMIDE/ ELVITEGRAVIR INSERT ADMINISTERED RECTALLY**  
11:08  
Sharon A. Riddler, Clifton Kelly, Craig Hoesley, Ken Ho, Jeanna Piper, Stacey Edick, Faye Heard, Yuqing Jiao, Gustavo F. Doncel, Sherri Johnson, Ratiya Pamela Kunjara Na Ayudhya, José Bauermeister, Craig Hendrix  
**Research Group:** MTN-039 Protocol Team

**165 ULTRA-LONG-ACTING REFILLABLE ISLATRAVIR IMPLANT FULLY PROTECTS NHP AGAINST SHIV**  
11:16  
Fernanda Pons-Faudoa, Nicola Di Trani, Corrine Ying Xuan Chua, Lane Bushman, Simone Capuani, Jocelyn Nikita Campa Carranza, Kathryn Shelton, Pramod Nehete, Joan Nichols, Jason Kimata, Peter L. Anderson, Roberto C. Arduino, Alessandro Grattoni, Charles Dobard, Gerardo Garcia-Lerma

# Getting the most out of CROI

- Be ready and willing to ask questions: in-person, on the WhatsApp at the MBC webinars
- Attend the MBC webinars each day
- Join the CROI Community 2023 WhatsApp group:  
<https://chat.whatsapp.com/Lakn5f9R2a9HhQvL7wgN6x>
- Consult each other, either on the WhatsApp, on the MBC webinars or in-person at the Advocates' Corner in the poster hall




# Take Care of Yourself

- You are not expected to know, understand, or learn it all
- Pace yourself and take breaks as needed:
  - *Step away from your screen!*
  - *Get some fresh air outside the conference center!*
- Have realistic expectations, be kind to yourself
- Remember everything is recorded, so you can revisit sessions or watch sessions you missed the first time
  - *Plenary lectures, symposia, oral abstract sessions, and themed discussions will be available as webcasts within 24hrs*

# Stay Connected!

- Margarita Breakfast Club – Daily virtual sessions that provide an intimate setting for dialogue between researchers and advocates on the hottest CROI science
- Join the Community WhatsApp Group and participate early and often <https://chat.whatsapp.com/Lakn5f9R2a9HhQvL7wgN6x>
- Share what you're hearing on social media using the official hashtag #CROI2023 (respect embargo – no tweets from abstracts until end of session)
- Follow conference coverage via aidsmap and AVAC on Twitter (@hivpxresearch)

# WhatsApp group




# Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques

**Victoria Walker-Sperling**



*Laboratory of Dan Barouch, Beth Israel Deaconess Medical Center, Harvard Medical School  
Boston, Massachusetts*

*Disclosure:* I have no financial relationships with any ineligible companies.



SIV+ Rhesus macaques have lower set point viral loads post-treatment interruption when treated with Ad26/MVA and a TLR7 agonist

Delay of viral rebound in SHIV+ Rhesus macaques treated with a TLR7 agonist and antibody PGT121











# Project Objective:

- To determine if giving ART-suppressed SHIV-infected macaques with a TLR7 agonist (vesatolimod) with **both** Ad26/MVA vaccination **and** PGT121 treatment will result in more frequent positive outcomes than either alone.



- 51 Rhesus macaques were infected intrarectally with SHIV-SF162P3 and treated from D9 onward with preformulated, daily ART (TDF, FTC, DTG).
  - Group 1: Ad26/MVA + PGT121 + Vesatolimod (N=12)
  - Group 2: Ad26/MVA + Vesatolimod (N=12)
  - Group 3: PGT121 + Vesatolimod (N=12)
  - Group 4: Sham (N=15)







All animals were fully suppressed during treatments and prior to ART discontinuation despite significant vesatolimod-induced activation of CD4 T cells





Ad26/MVA vaccination significantly increases the magnitude and breadth of cell-associated IFN $\gamma$  responses




Treatment with the triple combination resulted in the least amount of rebound and highest frequency of virologic control of the three groups



All interventions significantly reduced the set-point viral load compared sham treatment and PGT121 treatment significantly lowered the likelihood and time to viral rebound



# Larger breath and greater magnitude of cellular IFN $\gamma$ responses correlate with set-point viral load



# Conclusions

- The combination of vesatolimod, Ad26/MVA vaccination, and PGT121 administration resulted in 70% of animals exhibiting virologic control.
  - Four animals did not rebound & three controlled post-rebound.
- Combining passive and active immunization with vesatolimod resulted in more improved outcomes than either alone.



# Acknowledgements

**Dan Barouch, Beth Israel Deaconess**

**Medical Center**

Abi Chandrashekar

Joseph Nkolola

Erica Borducchi

Jinyan Liu

Noe Mercado

Virology, Protein, and Immunology Groups

**Mark Lewis, Bioqual**

**Bob & Janet Siliciano, Johns Hopkins University  
Medical School**

Emily Fray

Mithra Kumar

**Romas Geleziunas, Gilead Sciences**

Jeffrey Murry

Yunling Yang

**Nelson Michael & Merlin Robb, Walter Reed Army  
Institute of Research**

**Hanneke Schuitemaker, Janssen Vaccines and  
Prevention**

Maria Pau

Frank Wegmann

# Key Questions for Lay Audiences When Reviewing Research Looking to Boost Immune Function


- What are the products under investigation?
- What are the tests used to evaluate the effectiveness of the product?
- If it is an NHP study
  - What virus is being used and when did the animal start treatment (early vs. chronic infection)?
  - How many animals are included in the study?

# Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques

**Victoria Walker-Sperling**

*Laboratory of Dan Barouch, Beth Israel Deaconess Medical Center, Harvard Medical School  
Boston, Massachusetts*


*Disclosure:* I have no financial relationships with any ineligible companies.




SIV+ Rhesus macaques have lower set point viral loads post-treatment interruption when treated with Ad26/MVA and a TLR7 agonist

Delay of viral rebound in SHIV+ Rhesus macaques treated with a TLR7 agonist and antibody PGT121

### SIV RNA Following ART Discontinuation



Borducchi et al. Nature 2016; 540:284-287



**Background: 2 previous studies by the same group**

Borducchi et al. Nature 2018; 563:360-364

# Project Objective:


- To determine if giving ART-suppressed SHIV-infected macaques with a TLR7 agonist (vesatolimod) with **both** Ad26/MVA vaccination **and** PGT121 treatment will result in more frequent positive outcomes than either alone.

**Hypothesis statement: giving the monkeys 3 treatments that worked in the past will work better than only 2 together.**






- 51 Rhesus macaques were infected intrarectally with SHIV-SF162P3 and treated from D9 onward with preformulated, daily ART (TDF, FTC, DTG).

## Study Design

- Group 1: Ad26/MVA + PGT121 + Vesatolimod (N=12)
- Group 2: Ad26/MVA + Vesatolimod (N=12)
- Group 3: PGT121 + Vesatolimod (N=12)
- Group 4: Sham (N=15)




All animals were fully suppressed during treatments and prior to ART discontinuation despite significant vesatolimod-induced activation of CD4 T cells



**The monkeys had negative viral loads during the treatments**





Ad26/MVA vaccination significantly increases the magnitude and breadth of cell-associated IFN $\gamma$  responses

**The vaccine caused good immune responses.**






Treatment with the triple combination resulted in the least amount of rebound and highest frequency of virologic control of the three groups




**The triple treatment caused the most monkeys to have negative viral loads without ART.**

All interventions significantly reduced the set-point viral load compared sham treatment and PGT121 treatment significantly lowered the likelihood and time to viral rebound



**The triple treatment caused the lowest viral loads post-ART interruption and resulted in the fewest monkeys having the virus come back at all.**

Larger breath and greater magnitude of cellular IFN $\gamma$  responses correlate with set-point viral load



**The better the immune responses, the more likely for the post-ART viral loads to be lower.**

# Conclusions

- The combination of vesatolimod, Ad26/MVA vaccination, and PGT121 administration resulted in 70% of animals exhibiting virologic control.
  - Four animals did not rebound & three controlled post-rebound.
- Combining passive and active immunization with vesatolimod resulted in more improved outcomes than either alone.

**Using a vaccine, broadly neutralizing antibody, and an immune activator together prevented the virus from coming back in 70% of the monkeys after they were taken off ART, which was roughly better than just a combination of two.**

# Acknowledgements

**Dan Barouch, Beth Israel Deaconess**

**Medical Center**

Abi Chandrashekar

Joseph Nkolola

Erica Borducchi

Jinyan Liu

Noe Mercado

Virology, Protein, and Immunology Groups

**Mark Lewis, Bioqual**

**Bob & Janet Siliciano, Johns Hopkins University  
Medical School**

Emily Fray

Mithra Kumar

**Romas Geleziunas, Gilead Sciences**

Jeffrey Murry

Yunling Yang

**Nelson Michael & Merlin Robb, Walter Reed Army  
Institute of Research**

**Hanneke Schuitemaker, Janssen Vaccines and  
Prevention**

Maria Pau

Frank Wegmann